We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
-5.05%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$52.8M
(-30%)
Cap. Flow
+$7.71M
Cap. Flow
% of AUM
6.14%
Top 10 Holdings %
Top 10 Hldgs %
48.85%
Holding
64
New
14
Increased
25
Reduced
1
Closed
7
Avg Time Held Equity + Options
3.6
quarters
Top 10 Avg Time Held Equity + Options
1.5
quarters
Top 20 Avg Time Held Equity + Options
3.5
quarters
Avg Time Held Equity only
3.8
quarters
Top 10 Avg Time Held Equity only
2
quarters
Top 20 Avg Time Held Equity only
3.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$1.83M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$1.26M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.06M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$783K |
| 5 |
SCTL
Societal CDMO, Inc. Common Stock
SCTL
|
+$305K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares UltraShort S&P500
SDS
|
+$656K |
| 2 |
CPHD
Cepheid Inc
CPHD
|
+$315K |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$311K |
| 4 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$208K |
| 5 |
Novavax
NVAX
|
+$54K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.26% |
| 2 | Miscellaneous | 34.09% |
| 3 | Real Estate | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Precigen
PGEN
$2.76B
| $240K | 0.19% |
+9,964
| New | +$277K |
2016 Q4
0 quarters
|
|
|
AVXS
52
DELISTED
AveXis, Inc. Common Stock
AVXS
| $239K | 0.19% |
+5,000
| New | +$267K |
2016 Q4
0 quarters
|
|
53
Neurocrine Biosciences
NBIX
$14.4B
| $238K | 0.19% |
6,137
+2,069
| +51% | +$93.7K |
2016 Q3
1 quarter
|
|
54
Myriad Genetics
MYGN
$409M
| $232K | 0.18% |
+13,907
| New | +$252K |
2016 Q4
0 quarters
|
|
|
ICPT
55
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $232K | 0.18% |
2,135
+829
| +63% | +$98.8K |
2016 Q3
1 quarter
|
|
|
JUNO
56
DELISTED
Juno Therapeutics, Inc.
JUNO
| $216K | 0.17% |
11,478
+4,560
| +66% | +$112K |
2016 Q3
1 quarter
|
|
57
Seres Therapeutics
MCRB
$27.6M
| $139K | 0.11% |
700
| – | – |
2015 Q4
4 quarters
|
|
58
PUT
iShares Russell 2000 ETF
IWM
$78.3B
| – | – |
-350,000
| Closed | -$43.5M | – |
|
|
59
Novavax
NVAX
$2.08B
| – | – |
-1,289
| Closed | -$54K | – |
|
|
60
ProShares UltraShort S&P500
SDS
$348M
| – | – |
-400
| Closed | -$656K | – |
|
61
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| – | – |
-430,400
| Closed | -$28.5M | – |
|
|
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-6,746
| Closed | -$311K | – |
|
|
SIOX
63
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| – | – |
-1,856
| Closed | -$208K | – |
|
|
CPHD
64
DELISTED
Cepheid Inc
CPHD
| – | – |
-5,985
| Closed | -$315K | – |
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q4 2016 Portfolio in Review
As of Q4 2016, Opus Point Partners Management held 64 positions worth $126M, down 30% from $178M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Opus Point Partners Management deployed $7.71M of net new capital in Q4 2016, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was TESARO, Inc.: 10,000 shares worth $1.34M.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 44% a quarter earlier, followed by Miscellaneous and Real Estate.
On the sell side, the largest reduction was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $12.8K trimmed.
- Opus Point Partners Management's largest Q4 2016 buy was TESARO, Inc.: 10,000 shares worth $1.34M.
- Opus Point Partners Management added most to Alnylam Pharmaceuticals in Q4 2016, an estimated $1.83M increase.
- Opus Point Partners Management's biggest Q4 2016 reduction was Direxion Daily S&P Biotech Bull 3X ETF, cutting an estimated $12.8K.
- Opus Point Partners Management fully exited ProShares UltraShort S&P500 in Q4 2016, selling an estimated $656K.
- Opus Point Partners Management's ten largest holdings make up 49% of its $126M portfolio in Q4 2016.
- Opus Point Partners Management opened 14 new positions and closed 7 in Q4 2016.
- Opus Point Partners Management's portfolio value fell 30% quarter-over-quarter to $126M.
Based on Opus Point Partners Management's 13F filing for Q4 2016, filed 14 Feb 2017.